Digma Medical

Company Overview

Snapshot

Founded in January 2013 by Irit Yaniv and Ilan Ben-Oren, Digma Medical operates with 11–50 employees. The company has raised $2.36M across 4 funding rounds from 2 investors. In May 2022, Digma Medical secured funding from Peregrine Ventures.

Business overview

Digma Medical is a Health Tech & Life Sciences company focused on developing new therapies for type 2 diabetes. The company's core product is a minimally invasive therapy called Endoscopic Glycemic Management (EGM), which aims to restore the body’s natural ability to control blood glucose levels by targeting the duodenal submucosa. This treatment utilizes a console and a single-use catheter compatible with standard gastrointestinal endoscopes, designed to provide durable improvement in glycemic control without daily medication. Digma Medical serves hospitals, doctors, and healthcare providers in the medical devices and gastroenterology sectors.

Company Intelligence Q&A

What is Digma Medical's primary focus?

Digma Medical is developing a minimally invasive therapy, Endoscopic Glycemic Management (EGM), for the treatment of type 2 diabetes, aiming to restore natural blood glucose control.

When was Digma Medical founded and by whom?

Digma Medical was founded in January 2013 by Irit Yaniv and Ilan Ben-Oren.

Which investors have participated in Digma Medical's funding rounds?

Digma Medical has received funding from investors including Peregrine Ventures and Accelmed.

What is the total capital raised by Digma Medical?

Digma Medical has raised a total of $2.36M across 4 funding rounds.